73 related articles for article (PubMed ID: 3500981)
1. Selective in vivo antitumor effects of monoclonal anti-I-A antibody on B cell lymphoma.
Bridges SH; Kruisbeek AM; Longo DL
J Immunol; 1987 Dec; 139(12):4242-9. PubMed ID: 3500981
[TBL] [Abstract][Full Text] [Related]
2. Role of B cells in the stimulation of syngeneic mixed lymphocyte responses.
Thorbecke GJ; Chapman-Alexander J; Katz IR; Bienenstock A; Asofsky R
Behring Inst Mitt; 1983 May; (72):107-16. PubMed ID: 6242330
[TBL] [Abstract][Full Text] [Related]
3. Tumor-specific antigen of murine T-lymphoma defined with monoclonal antibody.
Allison JP; McIntyre BW; Bloch D
J Immunol; 1982 Nov; 129(5):2293-300. PubMed ID: 6181166
[TBL] [Abstract][Full Text] [Related]
4. Killing of rat adenocarcinoma 13762 in situ by adoptive transfer of CD4+ anti-tumor T cells requires tumor expression of cell surface MHC class II molecules.
Frey AB; Cestari S
Cell Immunol; 1997 May; 178(1):79-90. PubMed ID: 9184701
[TBL] [Abstract][Full Text] [Related]
5. Anti-CD45 and anti-CD52 (Campath) monoclonal antibodies effectively eliminate systematically disseminated human non-Hodgkin's lymphoma B cells in Scid mice.
de Kroon JF; de Paus RA; Kluin-Nelemans HC; Kluin PM; van Bergen CA; Munro AJ; Hale G; Willemze R; Falkenburg JH
Exp Hematol; 1996 Jul; 24(8):919-26. PubMed ID: 8690051
[TBL] [Abstract][Full Text] [Related]
6. Treatment of a murine B cell lymphoma with monoclonal antibodies and IL 2.
Berinstein N; Levy R
J Immunol; 1987 Aug; 139(3):971-6. PubMed ID: 3496394
[TBL] [Abstract][Full Text] [Related]
7. CpG oligodeoxynucleotide-induced immunity prevents growth of germinal center-derived B lymphoma cells.
Ponzio NM; Cutro S; Hu J; Marzouk A; Marshall JD
Int Immunopharmacol; 2006 Dec; 6(13-14):2057-68. PubMed ID: 17161362
[TBL] [Abstract][Full Text] [Related]
8. Deoxyribonucleic acid (DNA) encoding a pan-major histocompatibility complex class II peptide analogue augmented antigen-specific cellular immunity and suppressive effects on tumor growth elicited by DNA vaccine immunotherapy.
Teramoto K; Kontani K; Ozaki Y; Sawai S; Tezuka N; Nagata T; Fujino S; Itoh Y; Taguchi O; Koide Y; Asai T; Ohkubo I; Ogasawara K
Cancer Res; 2003 Nov; 63(22):7920-5. PubMed ID: 14633722
[TBL] [Abstract][Full Text] [Related]
9. Microscopic intratumoral dosimetry of radiolabeled antibodies is a critical determinant of successful radioimmunotherapy in B-cell lymphoma.
Du Y; Honeychurch J; Glennie M; Johnson P; Illidge T
Cancer Res; 2007 Feb; 67(3):1335-43. PubMed ID: 17283171
[TBL] [Abstract][Full Text] [Related]
10. Functional activity in vivo of effector T cell populations. II. Anti-tumor activity exhibited by syngeneic anti-MoMULV-specific cytolytic T cell clones.
Engers HD; Lahaye T; Sorenson GD; Glasebrook AL; Horvath C; Brunner KT
J Immunol; 1984 Sep; 133(3):1664-70. PubMed ID: 6205090
[TBL] [Abstract][Full Text] [Related]
11. Monoclonal antibody therapy of B cell lymphoma: signaling activity on tumor cells appears more important than recruitment of effectors.
Tutt AL; French RR; Illidge TM; Honeychurch J; McBride HM; Penfold CA; Fearon DT; Parkhouse RM; Klaus GG; Glennie MJ
J Immunol; 1998 Sep; 161(6):3176-85. PubMed ID: 9743386
[TBL] [Abstract][Full Text] [Related]
12. IA mutant functional antigen-presenting cell lines.
Glimcher LH; Hamano T; Asofsky R; Sachs DH; Pierres M; Samelson LE; Sharrow SO; Paul WE
J Immunol; 1983 May; 130(5):2287-94. PubMed ID: 6300242
[TBL] [Abstract][Full Text] [Related]
13. Description of a murine B lymphoma tumor-specific antigen.
Koch S; Zalcberg JR; McKenzie IF
J Immunol; 1984 Aug; 133(2):1070-7. PubMed ID: 6203965
[TBL] [Abstract][Full Text] [Related]
14. A human tumor xenograft model of therapy with a bispecific monoclonal antibody targeting c-erbB-2 and CD16.
Weiner LM; Holmes M; Adams GP; LaCreta F; Watts P; Garcia de Palazzo I
Cancer Res; 1993 Jan; 53(1):94-100. PubMed ID: 8093231
[TBL] [Abstract][Full Text] [Related]
15. Autoreactive and heat shock protein 60-recognizing CD4+ T-cells show antitumor activity against syngeneic fibrosarcoma.
Harada M; Matsuzaki G; Yoshikai Y; Kobayashi N; Kurosawa S; Takimoto H; Nomoto K
Cancer Res; 1993 Jan; 53(1):106-11. PubMed ID: 8093229
[TBL] [Abstract][Full Text] [Related]
16. Anti-4-1BB monoclonal antibody enhances rejection of large tumor burden by promoting survival but not clonal expansion of tumor-specific CD8+ T cells.
May KF; Chen L; Zheng P; Liu Y
Cancer Res; 2002 Jun; 62(12):3459-65. PubMed ID: 12067989
[TBL] [Abstract][Full Text] [Related]
17. Cell surface antigens expressed by subsets of pre-B cells and B cells.
McKearn JP; Baum C; Davie JM
J Immunol; 1984 Jan; 132(1):332-9. PubMed ID: 6606670
[TBL] [Abstract][Full Text] [Related]
18. Elimination of clonogenic tumor cells from human bone marrow using a combination of monoclonal antibody:ricin A chain conjugates.
Bregni M; De Fabritiis P; Raso V; Greenberger J; Lipton J; Nadler L; Rothstein L; Ritz J; Bast RC
Cancer Res; 1986 Mar; 46(3):1208-13. PubMed ID: 3510720
[TBL] [Abstract][Full Text] [Related]
19. Serological demonstration of an allogeneic Ia.7 antigen on the cell surface of SJL/J-derived reticulum cell sarcomas.
Wilbur SM; Marelli O; Bonavida B
Cancer Res; 1983 Sep; 43(9):4266-70. PubMed ID: 6347368
[TBL] [Abstract][Full Text] [Related]
20. Molecules recognized by anti-idiotypic monoclonal antibodies to the B cell lymphoma, BCL1.
Tamura GS; McGrath MS; Weissman IL
J Mol Cell Immunol; 1987; 3(4):243-53. PubMed ID: 3509925
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
